NZ560840A - Use of a combination of myxoma virus and rapamycin for therapeutic treatment - Google Patents

Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Info

Publication number
NZ560840A
NZ560840A NZ560840A NZ56084006A NZ560840A NZ 560840 A NZ560840 A NZ 560840A NZ 560840 A NZ560840 A NZ 560840A NZ 56084006 A NZ56084006 A NZ 56084006A NZ 560840 A NZ560840 A NZ 560840A
Authority
NZ
New Zealand
Prior art keywords
cells
cell
cancer
virus
myxoma virus
Prior art date
Application number
NZ560840A
Other languages
English (en)
Inventor
Grant Mcfadden
John Barrett
Marianne Stanford
Original Assignee
Robarts Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts Res Inst filed Critical Robarts Res Inst
Publication of NZ560840A publication Critical patent/NZ560840A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ560840A 2005-03-07 2006-03-06 Use of a combination of myxoma virus and rapamycin for therapeutic treatment NZ560840A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65881605P 2005-03-07 2005-03-07
PCT/CA2006/000315 WO2006094385A1 (en) 2005-03-07 2006-03-06 Use of a combination of myxoma virus and rapamycin for therapeutic treatment

Publications (1)

Publication Number Publication Date
NZ560840A true NZ560840A (en) 2009-07-31

Family

ID=36952904

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ560840A NZ560840A (en) 2005-03-07 2006-03-06 Use of a combination of myxoma virus and rapamycin for therapeutic treatment
NZ577283A NZ577283A (en) 2005-03-07 2006-03-06 Use of a Myxoma virus that does not express functional M135R

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ577283A NZ577283A (en) 2005-03-07 2006-03-06 Use of a Myxoma virus that does not express functional M135R

Country Status (14)

Country Link
US (5) US20090035276A1 (https=)
EP (2) EP1863906A4 (https=)
JP (2) JP2008531739A (https=)
KR (1) KR101479093B1 (https=)
CN (2) CN102357104B (https=)
AU (1) AU2006222500B2 (https=)
CA (1) CA2600675C (https=)
DK (1) DK2388315T3 (https=)
IL (2) IL185376A0 (https=)
MX (1) MX2007010962A (https=)
NZ (2) NZ560840A (https=)
RU (1) RU2461630C2 (https=)
UA (1) UA96412C2 (https=)
WO (1) WO2006094385A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006222500B2 (en) 2005-03-07 2011-09-01 Robarts Research Institute Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
MX2008015265A (es) * 2006-06-01 2008-12-12 Robarts Res Inst Mutates del virus de mixoma para tratamiento del cancer.
CN102124335B (zh) * 2008-05-22 2014-07-30 第一药品株式会社 基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
CN104039333B (zh) 2011-06-09 2018-11-16 佛罗里达大学研究基金会有限公司 移植物抗宿主疾病的治疗或预防方法
RU2695136C1 (ru) * 2018-06-19 2019-07-22 Общество с ограниченной ответственностью Биотехнология (ООО Биотехнология) Онколитический способ терапии рака молочной железы.
KR20210042135A (ko) 2018-08-08 2021-04-16 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 개선된 폭스바이러스 수율을 위한 방법
WO2020051248A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
US20220296660A1 (en) * 2019-09-02 2022-09-22 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for improving oncolytic virus infection for nonpermissive cancers
EP4041256A4 (en) * 2019-10-10 2023-11-08 Arizona Board of Regents on behalf of Arizona State University Oncolytic viruses that express multi-specific immune cell engagers
US20240091284A1 (en) * 2019-10-10 2024-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus comprising immunomodulatory transgenes and uses thereof
WO2022139440A1 (ko) * 2020-12-22 2022-06-30 바이로큐어 주식회사 신규한 재조합 믹소마바이러스 및 이의 용도

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
DE69722608T2 (de) 1996-01-25 2004-04-29 The University Court Of The University Of Glasgow, Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
JP2001510053A (ja) 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
US6264940B1 (en) * 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
AU6175000A (en) * 1999-07-12 2001-01-30 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
EP1955703A1 (en) * 1999-11-12 2008-08-13 Oncolytics Biotech Inc. Viruses for the treatment of cellular proliferative disorders
WO2001087324A1 (en) * 2000-05-17 2001-11-22 Viron Therapeutics, Inc. Compositions and methods for promoting immunosuppression
PL409579A1 (pl) * 2001-02-19 2015-03-02 Novartis Ag Leczenie raka
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
MXPA05009526A (es) * 2003-03-07 2005-12-15 Robarts Res Inst Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
ATE352301T1 (de) * 2003-04-22 2007-02-15 Wyeth Corp Antineoplastische zusammensetzungen
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
NZ550430A (en) * 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
AU2006222500B2 (en) 2005-03-07 2011-09-01 Robarts Research Institute Use of a combination of Myxoma virus and rapamycin for therapeutic treatment

Also Published As

Publication number Publication date
JP5674210B2 (ja) 2015-02-25
CN101137748B (zh) 2011-12-14
US20110195050A1 (en) 2011-08-11
US9987315B2 (en) 2018-06-05
EP2388315B1 (en) 2014-05-21
EP1863906A1 (en) 2007-12-12
JP2008531739A (ja) 2008-08-14
AU2006222500B2 (en) 2011-09-01
UA96412C2 (ru) 2011-11-10
HK1163175A1 (en) 2012-09-07
EP1863906A4 (en) 2009-06-03
WO2006094385A1 (en) 2006-09-14
US20090035276A1 (en) 2009-02-05
RU2007137008A (ru) 2009-04-20
EP2388315A3 (en) 2012-05-02
US20140134134A1 (en) 2014-05-15
CN102357104A (zh) 2012-02-22
AU2006222500A1 (en) 2006-09-14
CN101137748A (zh) 2008-03-05
CA2600675A1 (en) 2006-09-14
JP2012236860A (ja) 2012-12-06
RU2461630C2 (ru) 2012-09-20
IL185376A0 (en) 2008-02-09
CA2600675C (en) 2015-12-15
NZ577283A (en) 2010-11-26
US20130171106A1 (en) 2013-07-04
IL208070A0 (en) 2010-12-30
KR101479093B1 (ko) 2015-01-26
KR20070110423A (ko) 2007-11-16
US20180256656A1 (en) 2018-09-13
DK2388315T3 (da) 2014-08-25
CN102357104B (zh) 2016-01-27
MX2007010962A (es) 2008-03-10
EP2388315A2 (en) 2011-11-23
IL208070A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
US9987315B2 (en) Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
US8227440B2 (en) Use of Myxoma virus for the therapeutic treatment of cancer and chronic viral infection
HK1246149A1 (zh) 溶瘤牛痘病毒组合癌症疗法
HK1163175B (en) Use of a myxoma virus that does not express functional m135r for therapeutic treatment
CN100379453C (zh) 粘液瘤病毒在治疗癌症和慢性病毒感染中的用途
HK1081099B (en) Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
HK1188086A (en) Oncolytic vaccinia virus combination cancer therapy

Legal Events

Date Code Title Description
PSEA Patent sealed